Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 4, 2010, Pages 1616-1618

  Pasca, Maria Rosalia ^a   Degiacomi, Giulia ^a   Lopes Ribeiro, Ana Luisa De Jesus ^a,b   Zara, Francesca ^a   De Mori, Patrizia ^c   Heym, Beate ^d   Mirrione, Maurizio ^c   Brerra, Roberto ^a   Pagani, Laura ^a   Pucillo, Leopoldo ^c   Troupioti, Panajota ^e   Makarov, Vadim ^f   Cole, Stewart T ^g   Riccardi, Giovanna ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e Azienda Ospedaliera Della Valtellina e Valchiavenna   (Italy)

^f BACH INSTITUTE OF BIOCHEMISTRY   (Russian Federation)

^g EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIAZINONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; BASE SEQUENCE; DNA PRIMERS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; GENES, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; RACEMASES AND EPIMERASES; SPIRO COMPOUNDS; THIAZINES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77950141431     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01676-09     Document Type: Article

References (7)

1. Andersson, D. I. 2006. The biological cost of mutational antibiotic resistance: any practical conclusions? Curr. Opin. Microbiol. 9:461-465.
2. Christophe, T., M. Jackson, H. K. Jeon, D. Fenistein, M. Contreras-Dominguez, J. Kim, A. Genovesio, J. P. Carralot, F. Ewann, E. H. Kim, S. Y. Lee, S. Kang, M. J. Seo, E. J. Park, H. Škovierová, H. Pham, G. Riccardi, J. Nam, L. Marsollier, M. Kempf, M. L. Joly-Guillou, T. Oh, W. K. Shin, Z. No, U. Nehrbass, R. Brosch, S. T. Cole, and P. Brodin. 2009. High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 5:e1000645.
3. Makarov, V., G. Manina, K. Mikusova, U. Möllmann, O. Ryabova, B. Saint-Joanis, N. Dhar, M. R. Pasca, S. Buroni, A. P. Lucarelli, A. Milano, E. De Rossi, M. Belanova, A. Bobovska, P. Dianiskova, J. Kordulakova, C. Sala, E. Fullam, P. Schneider, J. D. McKinney, P. Brodin, T. Christophe, S. Waddell, P. Butcher, J. Albrethsen, I. Rosenkrands, R. Brosch, V. Nandi, S. Bharath, S. Gaonkar, R. K. Shandil, V. Balasubramanian, T. Balganesh, S. Tyagi, J. Grosset, G. Riccardi, and S. T. Cole. 2009. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324:801-804.
4. Riccardi, G., M. R. Pasca, and S. Buroni. 2009. Mycobacterium tuberculosis: drug resistance and future perspectives. Future Microbiol. 4:597-614.
5. Sassetti, C. M., D. H. Boyd, and E. J. Rubin. 2003. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 48:77-84.
6. Shenoi, S., S. Heysell, A. Moll, and G. Friedland. 2009. Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Curr. Opin. Infect. Dis. 22:11-17.
7. Wolucka, B. A. 2008. Biosynthesis of D-arabinose in mycobacteria - a novel bacterial pathway with implications for antimycobacterial therapy. FEBS J. 275:2691-2711.